Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J. van den Bent, Johan M. Kros, Roberta Rudà et al.|The Lancet|2017Cited by 401
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J. van den Bent, Brigitta G. Baumert, C. Mircea S. Tesileanu et al.|The Lancet Oncology|2021Cited by 333
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M. Clément, Martin J. van den Bent, Linda Dirven et al.|European Journal of Cancer|2021Cited by 20
LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410Martin J. van den Bent, Vassilis Golfinopoulos, Marica Eoli et al.|Neuro-Oncology|2017Cited by 14
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Martin J. van den Bent, Vassilis Golfinopoulos, Pim J. French et al.|Journal of Clinical Oncology|2018Cited by 14